25/09/2018 (Agence Europe) – The European Medicines Agency warned on 24 September that Brexit could disrupt access to 39 medicines (25 for human beings and 14 for animals) that have received a centralised marketing permit. In July, it estimated the number would be 108 (of the 694 products with centralised authorisation). Under EU law, the marketing authorisation holder, the QPPV (person qualified for pharmacovigilance), the PSMF (permanent pharmacovigilance system file) and certain...